Provided by Tiger Trade Technology Pte. Ltd.

Anaptysbio Inc

58.44
+0.70001.21%
Post-market: 57.51-0.9300-1.59%19:30 EDT
Volume:627.05K
Turnover:36.45M
Market Cap:1.73B
PE:-64.60
High:59.07
Open:56.96
Low:55.57
Close:57.74
52wk High:73.30
52wk Low:17.11
Shares:29.61M
Float Shares:21.05M
Volume Ratio:2.11
T/O Rate:2.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9047
EPS(LYR):-0.4601
ROE:-114.55%
ROA:6.78%
PB:135.74
PE(LYR):-127.01

Loading ...

Piper Sandler Releases a Buy Rating on AnaptysBio (ANAB)

TIPRANKS
·
May 04

Assessing AnaptysBio’s Valuation After Strong Recent Share Price Momentum

Simply Wall St.
·
May 03

U.S. Earnings Preview: After Market Close May 1

Dow Jones
·
May 02

AnaptysBio Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Apr 28

AnaptysBio Inc : Leerink Partners Raises Target Price to $85.00 From $66.00

THOMSON REUTERS
·
Apr 28

AnaptysBio Shares Rise After Delaware Court Dismisses Tesaro Claim

Dow Jones
·
Apr 28

BRIEF-GSK Says Unit Tesaro's Claim For Declaratory Judgment Against Anaptysbio Unchanged

Reuters
·
Apr 27

GSK: GSK and Tesaro Firmly of View That Allegations Are Entirely Without Merit and Remain Focused on Pursuing That Claim at Trial

THOMSON REUTERS
·
Apr 27

AnaptysBio files amended 8-K with pro forma financials for First Tracks spin-off

Reuters
·
Apr 25

AnaptysBio Inc - Court Ruling Preserves Current Royalty Rates and Rejects Tesaro's Royalty Reduction Request

THOMSON REUTERS
·
Apr 25

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim

THOMSON REUTERS
·
Apr 25

Delaware Chancery Court dismisses Tesaro anticipatory breach claim against AnaptysBio

Reuters
·
Apr 25

Assessing AnaptysBio (ANAB) Valuation As It Shifts To A Royalty Focus After Spinning Off Operations

Simply Wall St.
·
Apr 24

First Tracks Biotherapeutics initial beneficial ownership filing shows EcoR1 Capital stake

Reuters
·
Apr 23

AnaptysBio price target lowered to $60 from $90 at UBS

TIPRANKS
·
Apr 22

UBS Adjusts Price Target on AnaptysBio to $60 From $90, Maintains Buy Rating

MT Newswires Live
·
Apr 22

AnaptysBio Is Maintained at Buy by UBS

Dow Jones
·
Apr 22

AnaptysBio price target lowered to $60 from $90 at UBS

TIPRANKS
·
Apr 21

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Apr 21

AnaptysBio Completes Spinoff of First Tracks Biotherapeutics; Shares Surge

MT Newswires Live
·
Apr 20